Navigation Links
Dual role in breast tissue for a protein involved in leukemia
Date:6/12/2009

Washington, DC - A protein known to play a role in growth of some types of leukemia appears to have a mixed function in breast cancer development, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC).

The findings, presented at the annual meeting of the Endocrine Society in Washington, DC, indicate that the function of this protein, known as Stat5a, may be different in developing breast cancer cells that are estrogen receptor-positive as compared to estrogen receptor-negative. When estrogen receptor levels were overexpressed, loss of Stat5a reduced development of a lobular type of preneoplasia. However, when estrogen receptor levels were normal, loss of Stat5a not only had no effect on reducing preneoplasia, but increased susceptibility to carcinogen-induced breast cancer. The results illustrate the importance of breast cancer heterogeneity when testing new therapeutic targets.

The researchers say Stat5a could be a target for treatment of leukemia, but add, "If Stat5a is to be used as a drug target for leukemia or other cancers, it is important to fully understand how altering its function impacts the breast, especially since it appears it may play different roles in different types of breast cancer," says the study's lead author, Anne Miermont, MS, a doctoral graduate student in tumor biology at Georgetown University Medical Center.

Stat5a is a member of the STAT family of proteins, which are key to regulating cell growth and differentiation. Because they have been found to be over-expressed in leukemia, Miermont and Priscilla Furth, MD, a professor of oncology, sought to see if they were important in breast cancer development. Estrogen receptors are over-expressed in more than half of human breast cancers, so the investigators set up studies to test if the function of Stat5a was the same or different in cells with estrogen receptor overexpression.

They found that Stat5a A is rather
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Dioxins in food chain linked to breastfeeding ills
2. Wet ear wax and unpleasant body odors signal breast cancer risk
3. Breastfeeding duration and weaning diet may shape childs body composition
4. Lombardi scientist brings dream team breast cancer research effort to GUMC
5. Genetic testing for breast or ovarian cancer risk may be greatly underutilized
6. UNC study identifies genetic cause of most common form of breast cancer
7. IMPAKT -- Breast cancer conference highlights
8. Breast health center gives TGen new research opportunities
9. UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs
10. Twin nanoparticle shown effective at targeting, killing breast cancer cells
11. Red wine vs. white? It makes no difference when it comes to breast-cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 2005, President George W. Bush and American corn farmers saw ... reduce both American dependence on foreign oil and greenhouse gas ... gallons of renewable fuel be added to the gasoline supply ... and 7.5 billion in 2012. Since then, life cycle ...
... Using the meticulous phenological records of two iconic American naturalists, ... native plants in the eastern United States are flowering as ... climate. The new study is important because it gives ... in response to a warming world. In addition, the work ...
... 16, 2013 EcoHealth Alliance, a nonprofit organization that focuses ... on Ebola virus in fruit bats in the peer reviewed ... the Centers for Disease Control and Prevention (CDC). The ... 276 bats scientists screened in Bangladesh. These results suggest ...
Cached Biology News:Photovoltaics beat biofuels at converting sun's energy to miles driven 2Photovoltaics beat biofuels at converting sun's energy to miles driven 3In the Eastern US, spring flowers keep pace with warming climate 2In the Eastern US, spring flowers keep pace with warming climate 3Recent study suggests bats are reservoir for ebola virus in Bangladesh 2
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Technologies, Inc. , a developer and provider of medical ... second quarter results Tuesday morning, showing both growth and ... high of $18.8 million, the company took a loss ... owing largely to merger and transition costs after acquiring ...
... Madison, Wis. - Esker Software , a provider ... opening of a new mail house at its U.S. headquarters ... Esker on Demand service. , ,The new mail ... facility in Lyon, France and its strategic partners in the ...
... has been appointed to the board of directors of ... former president of the American Society of Therapeutic Radiation ... radiation oncology. , ,Perez is professor emeritus in ... Radiology, Siteman Cancer Center, Washington University Medical Center. , ...
Cached Biology Technology:Cedara acquisition costs hit Merge Technologies numbers 2
...
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
Biology Products: